Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
What's Inside the Box
Its the one that matches how you want your care structured
The SURMOUNT-1 trial (tirzepatide, published in NEJM 2022) demonstrated that participants with obesity or overweight without diabetes who received tirzepatide experienced weight reductions of 16.0% (5mg), 21.4% (10mg), and 22.5% (15mg) over 72 weeks
Further 2025 reviews highlight its safety and efficacy in improving insulin sensitivity in overweight, insulin-resistant cohorts (439)
For someone with a body mass index (BMI) over 35 and metabolic issues, its clearly medical
On the Cagrilintide side, the value of the standalone phase 2 trial is that it isolates the amylin effect from any GLP-1 contribution
US$ 29.30
US$ 21.49
US$ 27.39
US$ 23.26
US$ 25.71
US$ 29.07
US$ 25.43
US$ 24.40
US$ 22.42
